Eravacycline (ERV) is a novel, fully synthetic fluorocycline that has been evaluated in 3 comparator-controlled studies (1 phase 2 and 2 phase 3 [IGNITE1 and IGNITE4]) for the treatment of complicated intra-abdominal infections.1 These double-blind, double-dummy, multicenter studies compared ERV 1 mg/kg intravenously (IV) every 12 hours with the carbapenems, ertapenem 1 g IV every 24 hours or meropenem 1 g IV every 8 hours.1
This analysis reports the microbiological response at the test-of-cure (TOC) visit in the 2 treatment groups.2 Favorable microbiological response rates at the TOC visit were determined for each baseline pathogen isolated from blood and/or intra- or extra-abdominal specimens in the micro–intention-to-treat populations. For patients with infections caused by Enterobacteriaceae, the overall favorable clinical response rates for ERV-treated patients were 86.3% and 91.8% for IGNITE1 and IGNITE4, respectively.
The favorable microbiological response rates among pooled ERV-treated subjects were: Enterobacteriaceae, 88.2%; Escherichia coli, 88.1%; Enterobacter cloacae, 85.7%; Klebsiella pneumoniae, 97.4%; Acinetobacter baumannii, 100%; Streptococcus viridans group, Enterococcus faecalis, 83.3%; Enterococcus faecium, 86.7%; Staphylococcus aureus, 100%; and Bacteroides fragilis, 88.1%.
More than 88% of 5 Enterobacteriaceae spp and B fragilis, the most common bacteria associated with intra-abdominal infections, were eradicated by ERV. Eradication rates were comparable following ertapenem and meropenem therapy.
These data support in vitro observations that ERV has broad-spectrum activity against common isolates found in intra-abdominal infections.
- Efimova E, et al. IDWeek 2018. Abstract 1976.
- Newman J, et al. IDWeek 2018. Abstract 1963.